4KH Stock Overview
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Khiron Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.022 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.016 |
| Beta | 3.14 |
| 1 Month Change | 0% |
| 3 Month Change | 1.89% |
| 1 Year Change | -75.57% |
| 3 Year Change | -92.85% |
| 5 Year Change | n/a |
| Change since IPO | -97.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4KH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.7% |
| 1Y | -75.6% | -30.1% | 1.4% |
Return vs Industry: 4KH underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 4KH underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4KH volatility | |
|---|---|
| 4KH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4KH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4KH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Alvaro Torres | khiron.ca |
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis.
Khiron Life Sciences Corp. Fundamentals Summary
| 4KH fundamental statistics | |
|---|---|
| Market cap | €6.31m |
| Earnings (TTM) | -€20.82m |
| Revenue (TTM) | €10.96m |
0.6x
P/S Ratio-0.3x
P/E RatioIs 4KH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4KH income statement (TTM) | |
|---|---|
| Revenue | CA$16.14m |
| Cost of Revenue | CA$9.47m |
| Gross Profit | CA$6.67m |
| Other Expenses | CA$37.33m |
| Earnings | -CA$30.66m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 41.34% |
| Net Profit Margin | -190.00% |
| Debt/Equity Ratio | 3.0% |
How did 4KH perform over the long term?
See historical performance and comparison